Type 2 Diabetes Clinical Trial
Official title:
Beneficial Effects of Quinoa (Chenopodium Quinoa Willd) in the Prevention of Type 2 Diabetes Mellitus
Quinoa is a pseudo-cereal and has potential health benefits and exceptional nutritional
value. It is a food rich in proteins of high biological value, in unsaturated fats and fiber,
it is also a grain low in carbohydrates and with a low glycemic index. Concretely, quinoa
could produce a benefit on postprandial glycemia that would result in lower type 2 diabetes
(T2D) incidence.
A cross-over design pilot clinical study with a nutritional intervention for 8 weeks were
performed: 4 weeks on a regular diet (RD) and 4 weeks on a quinoa diet (QD). Nine subjects
aged ≥65 years with prediabetes were monitored during the first 4 weeks of RD with daily
dietary records and FreeStyle Libre®. Subsequently, participants started the DQ where quinoa
and 100% quinoa-based products replaced foods rich in complex carbohydrates that they
regularly consumed by the first 4 weeks of DR.
The glycemic measurements recorded by the sensors were considered as functions of time and
the effects of nutrients consumed at the intended time period were analyzed by means of
function on scalar regression (fosr) model.
The study was a cross-over pilot clinical study consisting of two periods. The first period
was only an observational and monitoring phase where participants just continued with their
regular diet (RD), for this reason all participants initiated this period and wash-out term
was no needed. Subsequently, with the data of the first phase obtained, the subjects began
the second period in which they had to undergo a nutritional intervention with a quinoa diet
(QD).
A total of six visits plus two quinoa products collection days were programmed. After the
pre-study visit (V0) which took place a week before start nutritional intervention and where
researchers obtained signed informed consent, participants were summoned for a first visit
(V1) where they were explained how they should fill in the dietary records and they were
applied with the FreeStyle Libre®.
Subjects then began RD, a period of 4 weeks during which only their normal life was
monitored. After the first 14 days of this, a second visit (V2) was made where the dietary
record was collected that would serve to account for their usual consumption of cereals,
flours, tubers and legumes, the FreeStyle Libre® sensor was also collected.
The last day on RD period, on day 28, they were cited (V3) in consultation where blood
samples after an 8 hours fast, anthropometrics measurements and blood pressure measure where
obtained and for the placement of the new FreeStyle Libre® sensor. Participants were asked
about their physical activity and exercise practice during those past 4 weeks by a short
questionnaire adapted from the Minnesota Leisure Time Physical Activity Questionnaire for
individuals of advanced age (VREM questionnaire) and a new empty 14-day dietary record was
given. In addition, the volunteers received the first foods with quinoa to initiate QD the
next day. Products were delivered weekly, for conservation reasons but also to ensure that
they followed an adequate consumption, they had to go through consultation to pick up the
product and gave the researchers the empty packs where quinoa products had been.
On the next visit the day 42 (V4) the Freestyle Libre® sensor was collected and the filled
dietary record was collected. Finally, after 28 days of quinoa diet they were summoned for
the last visit the day 56 (V5) where all the determinations were repeated identically as V3.
With the premise that the products created replaced not only grains, legumes or tubers, but
also farinaceous commonly consumed by the participants and that only the cereal fraction was
modified, similar products based on quinoa flour were created. The creation of these products
was necessary, after conducting a market search where it was observed that there was not
enough food to replace those consumed since these had percentages of quinoa flour not
exceeding 20-30%.
Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they
were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche,
sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was
delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of
the recipe. Each subject received the equivalent of what they consumed according to their RD
dietary records. Thus, only if the volunteer had indicated that he consumed sponge cake was
the quinoa-based product delivered to him.
Descriptive data are presented as the mean and standard deviation (SD) or median and
interquartile range (IQR) for continuous variables, and the frequencies and percentages (%)
for categorical variables. Anthropometric measurements, blood test variables and dietary
intake were compared at different times using the non-parametric Wilcoxon signed rank test
because normality and equality of variance could not be assumed due to small sample size
(n=9). In order to compare variables related to dietary patterns, mean value for dietary
intake, including all meals, was considered for each participant.
The glucose level monitoring sensor takes measurements at discrete time points for each
patient. Therefore, firstly the glucose curves have been linearly interpolated in order to
have observations for each patient at equal time points. A first sight to the glucose curves
over the day shown that they were more homogeneous around breakfast than around other later
meals intakes. Therefore, the glucose concentration values corresponding to the breakfast
were considered as a function of time in minutes over the interval t= [-30,120], that begins
half an hour before the start of breakfast and ends two hours later. Before constructing a
functional model, the functional data were time aligned in order to reduce the differences
between different patients and/or different days (for instance, some patients could mark the
starting time of breakfast systematically before than others, or spend systematically more
time in breakfast than the average). The time alignment has been done by warping functions,
using the function WFDA in the R package fdapace.
Once the glucose level curves have been synchronized, a functional regression analysis was
conducted to model the effect of diet type, patient and nutrient intake on monitored glucose
levels. Three different explanatory variables have been considered: diet type with two
categories (regular and Quinoa diets), patient indicator (categorical variable with nine
levels) and the contents in different nutrients. The breakfast glucose curves are handled as
the functional response variable. To study the relationship between these variables function
on scalar regression (fosr) models were used.
Firstly, the univariate effect of the diet type on glucose curves have been analyzed and then
more complex fosr models with two factors (diet and patient factors) and scalar variables
(nutrients) have been constructed. The most complex model including all effects of the
independent variables is defined by a specific-created equation. The functional regression
models have been fitted by penalized flexible functional regression, as implemented in the
function pffr of the R package refund.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |